Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma - SPARCC

NCT07123090 is registered in ClinicalTrials.gov with Stephanie Berg as lead sponsor.

NCT NCT07123090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07123090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma - SPARCC
Lead sponsor
Stephanie Berg
Phase
Phase 2
Overall status
Recruiting
Start date
November 24, 2025
Completion date
April 1, 2028
Enrollment
25 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced clear cell renal cell carcinoma, kidney cancer, metastatic renal cancer, metastatic renal cell carcinoma, renal cell carcinoma, translocation renal cell carcinoma